Guselkumab (IL-23i) 52 week extension study in PsA pts from DISCOVER 1 and 2 ⭐️sustained DAPSA LDA/remission ⭐️sustained PASDAS LDA/vLDA ⭐️sustained MDA POS1024 #EULAR2021 @RheumNow

C-VIEW Study: Certolizumab reduced Anterior Uveitis flares in AxSpA ⭐️82% ⬇️ in uveitis flare event ⭐️reduction in axSpA disease activity ⭐️no new safety signals POS0897 #EULAR2021 @RheumNow https://t.co/182iHfkSTY

Longitudinal UK SLE inception cohort 273 pts found: 👉⬆️damage in 1st 3 yrs b/f stabilizing at lower rate 👉mortality uncommon in 1st 12 yrs, but can occur w/in 5 yrs of Dx. 👉unexpected⬆️mortality in Caucasians 38% deaths IHD, 23% infx Abst#0111 #EULAR2021 @rheumnow @Lupusdoc https://t.co/wUwWaB4V2R

Can you predict flares in SLE pts who achieved LLDAS? Retrospec cohort study from Portugal over 3 years of 292 pts who were in LLDAS, 31% flared. Flares seen more in: 👉pts who require ongoing Rx w/ immmunosuppr, GCs 👉pt w/+RNP Abst#0105 #EULAR2021 @RheumNow https://t.co/xfBqGh4pPP

C3 and C4⬆️in SLE pregnancy like they would in pregnancies w/o SLE! French GR2 prospective study of 290 SLE pregnancies quantifies mean C3 value⬆️by 28%, C4⬆️by 11% from 1st ➡️3rd trimester. Remember this when assessing disease activity. #EULAR2021 Abstr #0103 @rheumnow https://t.co/TXjO4mjNJE

Definition of LLDAS: "A state assc w/low likelihood of adverse outcome, considering disease activity and medication safety; it must be favorable, deployable, feasible, and attainable," - Dr. E Morand #EULAR2021 @RheumNow https://t.co/oMMU3AjhmX

Quick update from #EULAR2021! Patient reported outcomes are important but how can we use them clinically in a meaningful way. Some key SpA/PsA findings from the experts at ASRI and the CorEvitas registry @rheumnow https://t.co/irxQs7Yzrx

Dr. G Robinson Abstr#OP0013 on sex link b/t autoimmune & CV risk 👉Hormones drive funx change in Treg transciptome 👉anti-inflamm Tregs⬆️in males 👉Tregs are more suppressive in males 👉Treg transciptome profile altered b/t males & females in autoimmunity #EULAR2021 @rheumnow https://t.co/p4Awfu2hiK

In DESIR AxSpA cohort: only 25% of patients achieved remission at 5 year follow up!!! Lower SES and ^ weight were negative factors in remission. Abstract #OP0052 #EULAR2021 @RheumNow https://t.co/X4wN1wIGfX https://t.co/DKBIXmEmki

• https://ard.bmj.com/content/80/Suppl_1/27.1.full

Female AxSpA pts report worse PROs but have better spinal mobility vs male AxSpA pts. Dz activity pattern similar in 4/6 BASDAI components regardless of gender. Females reports ^ fatigue, males report ^ spinal pain. Abstract# OP0051 #EULAR2021 @RheumNow https://t.co/U8T8JEWwCp https://t.co/yNP6PuA8PD

• https://ard.bmj.com/content/80/Suppl_1/27.2

ProDERM study (95 pts): RBPCT phase III IVIG 10% is effective in dermatomyositis (2 g/kg over 2-5 days q4 weeks. (common AEs: HA, fever, nausea most common AEs, rare SAE include thrombosis, LoC, hypoesthesia). Dr. R Aggarwal Abstr#OP008 #EULAR2021 @RheumNow https://t.co/ScTdUySxOl

Put out cigarettes around others! 👉passive smoking in childhood & adulthood⬆️RA risk 👉RA occurs earlier for passive smoking in childhood 👉passive smoking can cause citrullination in genetically proned subjects b/f 1st Sx's Dr. Y Nguyen Abstr#OP0012 #EULAR2021 @rheumnow https://t.co/ZoIumNQQAf

Flow&digital cytometry in early Rx-naive RA disting immunophenotypes in periph blood & dz tissue. Dr. F Rivellese Abst#OP0011 👉B cells invers correl w/inflamm'n & dz activity 👉Tph cells are potential markers of synov inflamm'n & predict clinical outcomes #EULAR2021 @rheumnow https://t.co/5GLx0espBX

Plenary abstract #OP0013. In autoimmunity: Male lipoprotein profile: ^ CV risk, but had ^ anti-inflammatory features vs females, 2/2 sex hormones. Possible pathway to dx and tx of inflammatory disease in the future? #EULAR2021 @RheumNow @eular_org https://t.co/Z2KmEQftve

• https://ard.bmj.com/content/80/Suppl_1/8.1.full

Differences in PROs found in CORRONA(now CorEvitas) PsA/SpA registry Ax-PsA and AxSpA patients. Can we better use PROs for disease characterization/differentiation? Abstract #OP0049 #EULAR2021 @RheumNow https://t.co/uHW2FQe0A5 https://t.co/HuPPUTAC9Z

• https://ard.bmj.com/content/80/Suppl_1/26.1